The burgeoning landscape of therapeutic interventions for metabolic disorders has witnessed considerable attention focused on GLP-3 receptor agonists and, more recently, the dual GIP and GLP-3 receptor agonist https://mariamsqzo000652.corpfinwiki.com/9508429/glp_3_retatrutide_a_comparative_analysis